This inventor holds 24 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Immunology and Bioimplants. Top assignees: Peptide Technology Limited, Peptech Limited, Arana Therapeutics Limited. Active years: 1996-2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Sydney, AU (1998)
- Sheidow Park, AU (1998 - 2002)
- New South Wales, AU (1997 - 2003)
- Thornleigh, AU (1996 - 2005)
- Flagstaff Hill, AU (2009 - 2011)
Company Filing History:
9 out of 14 
6 out of 12 
5 out of 5 Years Active: 1996-2011
Areas of Expertise:
Title: Deborah Ann Rathjen: Pioneering Innovations in Bioengineering
Introduction: Deborah Ann Rathjen, a prominent inventor based in Flagstaff Hill, Australia, has made significant contributions to the field of bioengineering, particularly in the development of innovative pharmaceuticals and formulations. With an impressive portfolio of 24 patents, her work continues to influence and advance medical science.
Latest Patents: Among her latest patents, Rathjen has developed a bioimplant formulation comprising lecithin and stearin, aiming to enhance both pharmaceutical and veterinary applications. This formulation consists of about 2-30% (w/w) of at least one active agent, 0.5-20.0% (w/w) of a pore-forming agent including lecithin and an organic salt, alongside the balance being stearin. Another notable patent focuses on tumor necrosis factor binding ligands, which facilitate modifications to the biological activity of human tumor necrosis factor alpha (TNF). This invention inhibits fibrin deposition and procoagulant activity while maintaining TNF's receptor binding duties on tumor cells, showcasing her innovative approach in therapeutic development.
Career Highlights: Rathjen's career has been marked by her work with various organizations such as Peptide Technology Limited and Peptech Limited, where she has honed her skills in biopharmaceutical research and development. Her dedication to advancing healthcare solutions through biotechnological innovations is evident in her extensive patent portfolio.
Collaborations: Throughout her career, Deborah Ann Rathjen has collaborated with esteemed professionals, including Roger Aston and Antonio Ferrante. These partnerships have fostered a dynamic work environment focused on groundbreaking research, further enhancing the impact of her inventive contributions.
Conclusion: Deborah Ann Rathjen embodies the spirit of innovation in the realm of bioengineering. Her 24 patents reflect her commitment to developing transformative solutions that address critical healthcare needs. With ongoing initiatives and collaborations, she is poised to continue her influence on the future of medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile